MA37963A1 - Protéines de fusion pour traiter un syndrome métabolique - Google Patents

Protéines de fusion pour traiter un syndrome métabolique

Info

Publication number
MA37963A1
MA37963A1 MA37963A MA37963A MA37963A1 MA 37963 A1 MA37963 A1 MA 37963A1 MA 37963 A MA37963 A MA 37963A MA 37963 A MA37963 A MA 37963A MA 37963 A1 MA37963 A1 MA 37963A1
Authority
MA
Morocco
Prior art keywords
treat
fusion proteins
metabolic syndrome
fusion protein
adiposity
Prior art date
Application number
MA37963A
Other languages
English (en)
Inventor
Oliver Boscheinen
Matthias Dreyer
Paul Habermann
Hans-Ludwig Schaefer
Mark Sommerfeld
Thomas Langer
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46888349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37963(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA37963A1 publication Critical patent/MA37963A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne une protéine de fusion comprenant au moins un composé fgf-21 (facteur 21 de croissance fibroblastique) et au moins un agoniste de glp-1r (récepteur du peptide 1 de type glucagon), ainsi que des compositions pharmaceutiques, des utilisations médicales et des méthodes de traitement impliquant la protéine de fusion, en particulier dans le domaine du diabète, de la dyslipidémie, de l'obésité et/ou de l'adiposité.
MA37963A 2012-09-07 2013-09-04 Protéines de fusion pour traiter un syndrome métabolique MA37963A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12306072 2012-09-07
PCT/EP2013/068239 WO2014037373A1 (fr) 2012-09-07 2013-09-04 Protéines de fusion pour traiter un syndrome métabolique

Publications (1)

Publication Number Publication Date
MA37963A1 true MA37963A1 (fr) 2018-06-29

Family

ID=46888349

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37963A MA37963A1 (fr) 2012-09-07 2013-09-04 Protéines de fusion pour traiter un syndrome métabolique

Country Status (25)

Country Link
US (3) US20140073563A1 (fr)
EP (1) EP2892919A1 (fr)
JP (1) JP2015533483A (fr)
KR (1) KR20150043505A (fr)
CN (1) CN104736558A (fr)
AR (1) AR092456A1 (fr)
AU (1) AU2013311777B2 (fr)
BR (1) BR112015004734A2 (fr)
CA (1) CA2880929A1 (fr)
CL (1) CL2015000379A1 (fr)
CR (1) CR20150149A (fr)
DO (1) DOP2015000020A (fr)
EA (1) EA201590525A1 (fr)
GT (1) GT201500049A (fr)
HK (1) HK1207097A1 (fr)
IL (1) IL237032A0 (fr)
MA (1) MA37963A1 (fr)
MX (1) MX2015002985A (fr)
PE (1) PE20150648A1 (fr)
PH (1) PH12015500194A1 (fr)
SG (1) SG11201500682WA (fr)
TN (1) TN2015000053A1 (fr)
TW (1) TW201414750A (fr)
UY (1) UY35018A (fr)
WO (1) WO2014037373A1 (fr)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107501407B (zh) 2007-03-30 2022-03-18 Ambrx公司 经修饰fgf-21多肽和其用途
CN105601748B (zh) 2011-07-01 2021-08-27 恩格姆生物制药公司 用于代谢病症和疾病治疗的组合物、应用和方法
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
HK1214832A1 (zh) 2012-11-28 2016-08-05 恩格姆生物制药公司 用於代謝病症和疾病治療的組合物和方法
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
ES2915851T3 (es) 2012-12-27 2022-06-27 Ngm Biopharmaceuticals Inc Péptidos quiméricos de FGF19 para usar en el tratamiento de trastornos de ácidos biliares
CA2927592C (fr) 2013-10-28 2020-08-18 Ngm Biopharmaceuticals, Inc. Variants de fgf-19 pour le traitement d'un cancer ou d'une tumeur fgf-19-dependant
PE20170256A1 (es) 2014-01-24 2017-04-22 Ngm Biopharmaceuticals Inc Proteinas de union y sus metodos de uso
US20170065678A1 (en) 2014-03-11 2017-03-09 Novartis Ag Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
WO2015183890A2 (fr) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Méthodes et compositions pour le traitement de maladies et de troubles métaboliques
AU2015277438B2 (en) 2014-06-16 2020-02-27 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
IL282156B (en) * 2014-07-29 2022-07-01 Shenzhen Hightide Biopharmaceutical Ltd Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof
RU2729161C2 (ru) 2014-10-23 2020-08-04 ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. Фармацевтические композиции, содержащие варианты пептидов, и способы их применения
CN114805532A (zh) 2014-10-24 2022-07-29 百时美施贵宝公司 修饰的fgf-21多肽及其用途
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
AR103246A1 (es) * 2014-12-23 2017-04-26 Novo Nordiks As Derivados de fgf21 y sus usos
CN110204617B (zh) * 2014-12-31 2023-06-16 天境生物科技(上海)有限公司 含胰高血糖素样肽-1和免疫球蛋白杂合Fc的融合多肽及其用途
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
EA037478B1 (ru) 2015-08-04 2021-04-01 Дьюк Юниверсити Генетически кодируемые внутренне неупорядоченные полимеры-"невидимки" для доставки и способы их применения
KR102670157B1 (ko) * 2015-10-28 2024-05-29 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
UA127495C2 (uk) 2015-12-23 2023-09-13 Амджен Інк. Виділений антигензв'язуючий білок, який специфічно зв'язується з поліпептидом рецептора шлункового інгібіторного пептиду (gipr) людини, та фармацевтична композиція, яка його містить
SI3402811T1 (sl) 2016-01-13 2022-06-30 Novo Nordisk A/S Analogi EGF(A) z maščobnokislinskimi substituenti
CN109414474B (zh) * 2016-04-29 2024-07-02 诺维信公司 肝脏、胆道和胰腺障碍的治疗
WO2017210476A1 (fr) 2016-06-01 2017-12-07 Duke University Biocapteurs ne s'encrassant pas
CN106317226B (zh) * 2016-08-19 2017-09-05 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
US11123438B2 (en) 2016-08-19 2021-09-21 Ampsource Biopharma Shanghai Inc. Linker peptide for constructing fusion protein
CA3034399A1 (fr) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methodes de traitement de cancers et de tumeurs a mediation assuree par le facteur de croissance des fibroblastes 19
JP2020500150A (ja) 2016-09-23 2020-01-09 デューク ユニバーシティ 下限臨界溶液温度挙動を有する非反復かつ非構造的ポリペプチド
BR112019012693A2 (pt) * 2016-12-22 2019-11-19 Sanofi combinações de composto de fgf21/agonista do glp-1r com razão de atividade otimizada
WO2018132732A1 (fr) 2017-01-12 2018-07-19 Duke University Biomatériaux hybrides lipide-polypeptide génétiquement codés qui offrent un auto-assemblage hiérarchique déclenché par la température
IL313587A (en) 2017-01-17 2024-08-01 Amgen Inc Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
CN108440668A (zh) * 2017-02-16 2018-08-24 瑞阳(苏州)生物科技有限公司 Fgf21与igf-1的融合蛋白及其应用
WO2018166461A1 (fr) * 2017-03-14 2018-09-20 Sunshine Lake Pharma Co., Ltd. Protéines de fusion à double cible comprenant la partie fc d'une immunoglobuline
US11560416B2 (en) 2017-04-21 2023-01-24 Yuhan Corporation Method for producing dual function proteins and its derivatives
WO2018213320A1 (fr) 2017-05-15 2018-11-22 Duke University Production recombinante de matériaux hybrides lipidiques-biopolymères qui s'auto-assemblent et encapsulent des agents
EA201992502A1 (ru) 2017-06-20 2020-04-22 Эмджен Инк. Способ лечения или уменьшения интенсивности метаболических нарушений с применением белков, связывающих рецептор гастроингибиторного пептида (gipr), в комбинации с агонистами glp-1
EP3642238A1 (fr) 2017-06-21 2020-04-29 Amgen Inc. Méthode de traitement ou d'amélioration des troubles métaboliques à l'aide de protéines de liaison antagonistes pour protéines de fusion agonistes du récepteur du peptide inhibiteur gastrique (gipr)/récepteur glp-1
WO2019006374A1 (fr) 2017-06-30 2019-01-03 Duke University Ordre et désordre en tant que principe de conception pour des réseaux de biopolymère sensibles à des stimuli
CA3068956A1 (fr) 2017-07-19 2019-01-24 Novo Nordisk A/S Composes bifonctionnels
EP3684793A1 (fr) 2017-09-22 2020-07-29 Regeneron Pharmaceuticals, Inc. Agonistes du récepteur glp-1 (glucagon-like peptide 1) et leurs utilisations
CN111328346B (zh) * 2017-11-06 2023-06-23 西纳生物技术有限公司 基于人铁蛋白和蛋白酶可切割肽的融合蛋白及其作为化学治疗载体的用途
CN109836504B (zh) * 2017-11-24 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的多结构域活性蛋白
WO2019119673A1 (fr) 2017-12-19 2019-06-27 北京吉源生物科技有限公司 Cellule souche modifiée par deux gènes et utilisation de cette dernière
WO2019123427A1 (fr) 2017-12-22 2019-06-27 Novartis Ag Procédés de traitement de troubles métaboliques avec des variants de fgf21
CN110028587B (zh) * 2018-01-11 2021-10-08 安源医药科技（上海）有限公司 用于调节血糖和脂质的增效型双功能蛋白
WO2019147954A1 (fr) 2018-01-26 2019-08-01 Duke University Conjugués de médicament-peptidede liaison à l'albumine et méthodes de préparation et d'utilisation de ces derniers
AU2019218147B2 (en) * 2018-02-08 2023-06-08 Sunshine Lake Pharma Co., Ltd. FGF21 variant, fusion protein and application thereof
EP3788343B1 (fr) 2018-04-30 2024-03-27 Duke University Plateforme d'administration de médicament à base de polymère de type peg sensible aux stimuli
WO2019243557A1 (fr) 2018-06-21 2019-12-26 Sanofi Combinaisons associant le composé fgf21 et un agoniste du glp-1r selon un rapport optimisant leur activité
US11649275B2 (en) 2018-08-02 2023-05-16 Duke University Dual agonist fusion proteins
US12594347B2 (en) 2018-09-07 2026-04-07 Duke University Nanoparticulate drug delivery systems
CN109836486B (zh) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 成纤维生长因子21变体、其融合蛋白及其用途
CN111944055B (zh) * 2019-05-16 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
EP4085077A4 (fr) 2019-12-31 2024-01-17 Beijing QL Biopharmaceutical Co., Ltd. Protéines de fusion de glp-1 et de gdf15 et leurs conjugués
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
CN113735977A (zh) * 2020-05-28 2021-12-03 江苏康缘瑞翱生物医药科技有限公司 rhFGF21融合蛋白、编码其的多核苷酸、包含其组合物及其用途
US12054551B2 (en) 2020-07-02 2024-08-06 Sanofi FGFR1/KLB targeting agonistic antigen-binding proteins and conjugates thereof with GLP-1R agonistic peptides
US20230265152A1 (en) * 2020-07-02 2023-08-24 Sanofi Glp-1r agonist / fgf21 fusion proteins
WO2022010319A1 (fr) * 2020-07-10 2022-01-13 (주)지아이이노베이션 Protéine de fusion comprenant un peptide-1 de type glucagon et un antagoniste de récepteur de l'interleukine-1 et utilisation associée
WO2022117044A1 (fr) * 2020-12-03 2022-06-09 Sunshine Lake Pharma Co., Ltd. Polypeptide agoniste du récepteur double glp-1/gcg et sa protéine de fusion
TWI837615B (zh) * 2021-03-23 2024-04-01 美商美國禮來大藥廠 含腸促胰島素(incretin)類似物之組合物及其用途
CN113150172B (zh) * 2021-04-28 2023-09-22 中国药科大学 Glp-1r/gipr双靶点激动剂融合蛋白及其制备方法与应用
WO2022256568A1 (fr) * 2021-06-02 2022-12-08 Arizona Board Of Regents On Behalf Of The University Of Arizona Procédés et compositions pour la localisation de facteurs de croissance
WO2023284822A1 (fr) * 2021-07-14 2023-01-19 Beijing Ql Biopharmaceutical Co., Ltd. Polypeptides de fusion pour troubles métaboliques
CN113583142A (zh) * 2021-08-20 2021-11-02 赣江中药创新中心 双靶点融合蛋白、编码基因、载体或宿主细胞及其应用与表达和纯化方法
US20240383959A1 (en) * 2021-09-09 2024-11-21 Northwestern University Cell-free methods and compositions comprising tagless therapeutic hormones
WO2024064842A1 (fr) 2022-09-21 2024-03-28 Regeneron Pharmaceuticals, Inc. Méthodes de traitement de l'obésité, du diabète et de la dysfonction hépatique
WO2024097875A1 (fr) * 2022-11-02 2024-05-10 Shattuck Labs, Inc. Protéines de fusion pour le traitement de la stéatohépatite non alcoolique
WO2024123812A1 (fr) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Protéines de fusion pour le traitement de maladies cardiométaboliques
CN115991793A (zh) * 2023-01-16 2023-04-21 上海民为生物技术有限公司 具有多重活性的融合蛋白及其应用
WO2024165571A2 (fr) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibiteurs d'expression et/ou de fonction
KR20250167609A (ko) * 2023-03-30 2025-12-01 노보 노르디스크 에이/에스 융합 화합물 및 그 용도
KR20260010739A (ko) 2023-05-11 2026-01-21 유니버시티 하스피탈즈 클리블랜드 메디컬 센터 항불안 치료
WO2025125576A2 (fr) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibiteurs d'expression et/ou de fonction
WO2025133348A1 (fr) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibiteurs d'expression et/ou de fonction
EP4686757A1 (fr) 2024-07-31 2026-02-04 e-therapeutics PLC Inhibiteurs d expression et/ou de fonction
CN117801124A (zh) * 2024-02-29 2024-04-02 天津凯莱英生物科技有限公司 利西那肽前体的融合蛋白及其应用
CN117801125B (zh) * 2024-02-29 2024-05-24 天津凯莱英生物科技有限公司 艾塞那肽前体的融合蛋白及其应用
WO2025196502A1 (fr) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Inhibiteurs de choline kinase utilisés en tant que traitement thérapeutique contre l'obésité
CN119241721A (zh) * 2024-09-25 2025-01-03 郑州大学 一种重组人abd-irisin蛋白及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03219892A (ja) * 1990-01-24 1991-09-27 Kyowa Hakko Kogyo Co Ltd タンパク質の製造法
GB9725556D0 (en) * 1997-12-03 1998-02-04 Ciba Geigy Ag Organic compounds
HUP0105090A2 (hu) * 1999-01-07 2002-04-29 Lexigen Pharmaceuticals Corporation Kóros elhízás elleni fehérjék expressziója és exportja Fc fúziós fehérje formájában
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
CN1480466A (zh) * 2002-09-03 2004-03-10 �й������ž�����ҽѧ��ѧԺ����ҽ 一类溶栓抗凝双功能融合蛋白及应用
GEP20105110B (en) * 2004-08-03 2010-11-10 Transtech Pharma Inc Rage fusion proteins and their use
WO2007005604A2 (fr) * 2005-07-05 2007-01-11 The Regents Of The University Of California Polynucleotides codant pour des enzymes de modification d'isoprenoides et methodes d'utilisation de ceux-ci
US7625564B2 (en) * 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
PE20081140A1 (es) * 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
US20110034373A1 (en) * 2007-08-03 2011-02-10 Eli Lilly And Company Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
JP2010536341A (ja) * 2007-08-15 2010-12-02 アムニクス， インコーポレイテッド 生物学的に活性なポリペプチドの特性を改変するための組成物および方法
ES2610356T3 (es) * 2009-02-03 2017-04-27 Amunix Operating Inc. Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
CN101993485B (zh) * 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
AU2010306774A1 (en) * 2009-10-14 2012-05-03 Merrimack Pharmaceuticals, Inc. Bispecific binding agents targeting IGF-1R and ErbB3 signalling and uses thereof
WO2011084808A2 (fr) * 2009-12-21 2011-07-14 Amunix Operating Inc. Compositions de polypeptides bifonctionnels et procédés pour le traitement de maladies métaboliques et cardiovasculaires
EP2460527A1 (fr) * 2010-01-21 2012-06-06 Sanofi Composition pharmaceutique pour le traitement d'un syndrome métabolique
WO2012088608A1 (fr) * 2010-12-27 2012-07-05 Enobia Canada Limited Partnership Compositions contenant des peptides natriurétiques et leurs méthodes d'utilisation
UY34347A (es) * 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
EP2825557B1 (fr) * 2012-03-16 2017-06-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Fc monomère modifié soluble

Also Published As

Publication number Publication date
TW201414750A (zh) 2014-04-16
CR20150149A (es) 2015-05-29
HK1207097A1 (en) 2016-01-22
DOP2015000020A (es) 2015-04-15
US20160194371A1 (en) 2016-07-07
US20140073563A1 (en) 2014-03-13
CN104736558A (zh) 2015-06-24
AU2013311777A1 (en) 2015-03-19
WO2014037373A1 (fr) 2014-03-13
GT201500049A (es) 2016-02-15
UY35018A (es) 2014-03-31
SG11201500682WA (en) 2015-02-27
KR20150043505A (ko) 2015-04-22
CL2015000379A1 (es) 2015-06-05
AU2013311777B2 (en) 2018-02-01
PH12015500194A1 (en) 2015-04-20
EP2892919A1 (fr) 2015-07-15
PE20150648A1 (es) 2015-05-25
BR112015004734A2 (pt) 2017-11-21
AR092456A1 (es) 2015-04-22
CA2880929A1 (fr) 2014-03-13
MX2015002985A (es) 2015-06-22
IL237032A0 (en) 2015-03-31
US20190085043A1 (en) 2019-03-21
TN2015000053A1 (en) 2016-06-29
EA201590525A1 (ru) 2015-07-30
JP2015533483A (ja) 2015-11-26

Similar Documents

Publication Publication Date Title
MA37963A1 (fr) Protéines de fusion pour traiter un syndrome métabolique
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
EA201492053A1 (ru) Белки фактора роста фибробластов 21
EA201491161A1 (ru) Фторированные модуляторы рецепторов эстрогенов и их применение
MA35458B1 (fr) Variants du facteur de croissance des fibroblastes 21
EA201491644A1 (ru) Фармацевтические композиции
EA201270815A1 (ru) Модуляторы рецепторов эстрогена и их применение
EA201101524A1 (ru) Способ и композиция для лечения состояния, связанного с хемосенсорным рецептором
EA201201047A1 (ru) Способы и композиции, в которых применяют слитые полипептиды fgf 23
EA201390821A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты и их применение
EA201492064A1 (ru) Варианты фактора роста фибробластов 21
MA38406A1 (fr) Virus de la maladie de newcastle et leurs utilisations
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
MA46219B1 (fr) Composés de co-agonistes du glucagon et du glp-1
EA201101709A1 (ru) Полициклические антагонисты рецепторов лизофосфатидной кислоты
EA201792047A1 (ru) Новые соединения
EP1993560A4 (fr) Antagonistes de recepteur cannabinoide/agonistes inverses utiles dans le traitement de l'obesite
EA201491530A1 (ru) Модуляторы рецепторов эстрогенов и их применение
EA201591176A1 (ru) Композиции и способы с использованием пептидной метки, связывающейся с гиалуронаном
EA201270767A1 (ru) Терапия на основе лигандов хемосенсорных рецепторов
EA201590590A1 (ru) Модуляторы рецептора андрогенов и их применение
MX2014003579A (es) Peptidos de la superfamilia de glucagon que presentan actividad del receptor de glucocorticoide.
PE20161032A1 (es) Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion
EA201491496A1 (ru) Ингибиторы c-концевого домена hsp90
EA201690064A1 (ru) Антитела к лектин-подобному рецептору 1 окисленных ldl и способы применения